U.S.S.N 09/760,362 Chen PRELIMINARY AMENDMENT

generated leading to a number of biological effects resulting in damage to the endothelial membranes and ultimately to clotting of the neovasculature.

Please replace paragraph 007 on page 3, with the following paragraph:

In addition to neovascular tissue formation associated with diabetic retinopathy and age-related macular degeneration, the growth of new blood vessels is also associated with tumor formation in the eye, which results from two mechanisms: the stimulated growth of endothelial cells of existing blood vessels through angiogenesis; and a newly discovered vasculature resulting from highly malignant uveal melanomas, which develop in the eye, are full of networks of blood channels made by the melanoma cells themselves (Maniotis et al., American Journal of Pathology 155(3):739-52 (1999)). It may be that anti-angiogenic agents are ineffective in the treatment of such neovasculature arising not from endothelial cells, but from tumor cells such as those of malignant uveal melanomas.

Please replace paragraph 010 on page 4, with the following paragraph:

Regarding light sources for PDT, high powered lasers are usually employed in order to shorten the procedure time (see: Strong *et al.*, U.S. Patent Nos. 5,756,541 and 5,910,510; and Mori *et al.*, U.S. Patent No. 5,633,275; see more generally, W.G. Fisher, *et al.*, *Photochemistry and Photobiology*, 66(2):141-155, 1997).

Please replace paragraph 037 on page 10, with the following paragraph:

"Illumination" as used herein includes all wavelengths and wavebands. Preferably, the illumination wavelength or waveband is selected to match the wavelength(s) or wavebands which excite the photosensitive compound. Even more preferably, the radiation wavelength or waveband matches the excitation wavelength or waveband of the photosensitive compound and has low absorption by the non-target tissues of the eye, and the rest of the subject, including blood proteins.

*AMEL - REALMEN - LIGHTONIA /MON - TELL